Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. Capricor ( ) is a biotechnology company developing transformative therapeutics for diseases.

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

Capricor is pleased to be attending the 38th Annual Roth Conference this week in Dana Point, California. The annual conf...
03/23/2026

Capricor is pleased to be attending the 38th Annual Roth Conference this week in Dana Point, California. The annual conference brings together more than 400 public and private companies, along with investors, for expert-led panels and keynotes across a range of multiple sectors.

We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: https://bit.ly...
03/12/2026

We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: https://bit.ly/4bKdCcP
Our quarterly conference call begins at 4:30 p.m. ET – join the webcast here: https://bit.ly/3NjKRLy

Yesterday at , we presented late-breaking data from the Phase 3 HOPE-3 trial highlighting Deramiocel’s potential impact...
03/12/2026

Yesterday at , we presented late-breaking data from the Phase 3 HOPE-3 trial highlighting Deramiocel’s potential impact on functional outcomes in Duchenne muscular dystrophy.
Read the full release: https://bit.ly/3NfTTcE

We’re pleased to be attending the 2026 MDA Conference this week in Orlando, Florida. This important meeting brings toget...
03/10/2026

We’re pleased to be attending the 2026 MDA Conference this week in Orlando, Florida. This important meeting brings together clinicians, researchers and patient advocates to discuss the latest developments in Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.

Capricor will be featured in the late-breaking presentation on March 11 and will also be at Booth #407 during the meeting.
If you’re attending, please stop by and say hello.

Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular...
03/10/2026

Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026.
Click here to read the announcement: https://bit.ly/4bz2qk2

February 28 is Rare Disease Day 💜 Today, we stand with the more than 300 million people worldwide living with a rare dis...
02/28/2026

February 28 is Rare Disease Day 💜

Today, we stand with the more than 300 million people worldwide living with a rare disease — including those affected by Duchenne muscular dystrophy (DMD). At Capricor, our mission is clear: advance innovative therapies and work with urgency to bring new options to patients and families who need them most.

Today and every day, we remain focused on transforming innovation into hope.

We are pleased to share that Capricor has been selected for a late-breaking oral presentation at the 2026 MDA Clinical &...
02/24/2026

We are pleased to share that Capricor has been selected for a late-breaking oral presentation at the 2026 MDA Clinical & Scientific Conference featuring our Phase 3 HOPE-3 results, alongside the submission of the HOPE-3 clinical study report to the U.S. FDA in support of our ongoing BLA review.
To read the full announcement, click here: https://bit.ly/4cLtDB9

We are pleased to provide a regulatory update on Deramiocel following FDA review of the HOPE-3 topline data. The FDA has...
01/20/2026

We are pleased to provide a regulatory update on Deramiocel following FDA review of the HOPE-3 topline data. The FDA has requested the HOPE-3 clinical study report, an expected step as the BLA review progresses.
Click to read the release: https://bit.ly/4b8MiWU

Our CEO, Linda Marbán, joined Amy Brown on at the JPM Healthcare Conference to reflect on a meaningful year for our Duc...
01/14/2026

Our CEO, Linda Marbán, joined Amy Brown on at the JPM Healthcare Conference to reflect on a meaningful year for our Duchenne muscular dystrophy program. The conversation highlights key milestones for Deramiocel, including the Phase 3 HOPE-3 readout as well as next steps in the regulatory review and what this progress could mean for individuals and families in the DMD community.

Watch the full interview here: https://www.biotechtv.com/post/capricor-january-13-2026

In case you missed it: Parent Project Muscular Dystrophy and Capricor hosted a community webinar discussing positive top...
12/18/2025

In case you missed it: Parent Project Muscular Dystrophy and Capricor hosted a community webinar discussing positive topline results from the Phase 3 HOPE-3 trial evaluating Deramiocel in Duchenne muscular dystrophy, including a review of the data and how the findings inform ongoing regulatory discussions and next steps with the FDA.
Catch the webinar replay here: https://bit.ly/4p6zt2L

Today at 1:00 p.m. ET Join and Capricor for a community webinar discussing positive topline results from the Phase 3 HO...
12/17/2025

Today at 1:00 p.m. ET

Join and Capricor for a community webinar discussing positive topline results from the Phase 3 HOPE-3 trial evaluating Deramiocel in DMD. We’ll review the data and discuss how the findings inform ongoing regulatory discussions, including next steps with the FDA.

Read the press release: https://bit.ly/3KWo3jY

Register here: https://bit.ly/3KMGNCt

Today marks a defining moment for the Duchenne community. The U.S. Department of Health and Human Services has added Duc...
12/16/2025

Today marks a defining moment for the Duchenne community. The U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, expanding newborn screening nationwide—an important step toward earlier diagnosis and improved outcomes for families.
We are proud to stand alongside the community as this progress continues.

Address

10865 Road To The Cure
San Diego, CA
92121

Website

Alerts

Be the first to know and let us send you an email when Capricor Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Capricor Therapeutics, Inc.:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram